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Cancer induced bone pain
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Bone pain is the most common type of pain from cancer and is
present in around one third of patients with bone metastases.1 2
Based on postmortem studies of patients with advanced cancer
and clinical knowledge of how often bone metastases result in
pain, the incidence of cancer induced bone pain is estimated at
30 000 patients in the United Kingdom each year.3 w1 Currently,
improvements in cancer treatments mean that many patients are
living with metastatic cancer for several years. The prevalence
of cancer induced bone pain is therefore likely to be much
greater than the annual incidence.w1 Cancer induced bone pain
is considered one of the most difficult pain conditions to treat
because of its frequent association with weight bearing and
movement. Not surprisingly, it has a major impact on patients而
daily functioning and mood and can result in admission to
hospital.w2 w3
Given the prevalence of cancer induced bone pain, it is likely
that clinicians in primary or secondary care will be confronted
by patients in pain crises. Recognising and initiating
management of this specific pain state, as well as an awareness
of the specialist treatments, is important for all clinicians.
What is cancer induced bone pain?
Cancer induced bone pain is a specific pain state with
overlapping but distinct features of both inflammatory and
neuropathic pain.4 The most important changes are in bone
homeostasis, with corresponding events in the peripheral and
central nervous system.5 In healthy bone, osteoclasts and
osteoblasts are highly regulated to maintain balanced resorption
and formation of bone respectively, through RANK-ligand
(receptor activator of nuclear factor ぎ). In the presence of a bone
metastasis, increased expression of RANK-ligand disrupts this
relation leading to increased osteoclast activity and bone
destruction. Cancer cells also stimulate local inflammatory
mediators and create a highly acidic environment, which
sensitises peripheral nerve endings within the bone marrow and
bone matrix. When combined with the destruction of nerve
endings through cancer invasion, the resulting pain is a mixture
of ongoing inflammatory and neuropathic processes, which lead
to a hyperexcitability state within the spinal cord. Patients
experience this as constant pain, with high sensitivity to
movement.4
Who gets cancer induced bone pain?
Cancer induced bone pain can occur anywhere that cancer has
metastasised to bone. Cancers most often involved are those of
the prostate, breast, and lung, as well as myeloma.3 The most
common sites of metastases are vertebrae, pelvis, long bones,
and ribs.3 At postmortem examination, up to 70% of patients
who died of cancer will have bone metastases.3 Bone metastases
can be found in a wide range of places (figure松). However, not
all patients with bone metastases get pain; bone pain was
identified in only a third of patients with bone metastases in one
large prospective study.1 It is not yet clear why some bone
metastases cause pain and others do not.
What are the clinical features of cancer
induced bone pain?
In a cross sectional survey in 2011 patients described their
cancer induced bone pain as annoying, gnawing, aching, and
nagging.w4 The pain is commonly a mixture of steady
background pain, as well as pain that is exacerbated by weight
bearing or movement, called incident or episodic pain.4 In a
recent well conducted European-wide observational study of
1000 patients with cancer, 85.5% reported some form of incident
pain episodes.6 The presence of movement related pain has most
impact on function and daily activity.w4
Cancer induced bone pain is most commonly experienced in
the lower back, pelvis, long bones, and ribs. This can be the
presenting feature of the cancer or highlight a recurrence in
those previously treated. Therefore in patients with or without
active cancer, persistent pain in these areas should alert
clinicians to the possibility of bone metastases. Findings on
examination are often non-specific with only some tenderness
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Cancer induced bone pain is a common problem, which can be extremely debilitating to patients with an already limited life expectancy
When treating cancer induced bone pain, maintenance of function should be given high priority alongside pain relief
Early recognition, intervention with functional aids, and behaviour modification, combined with initial titration with analgesia (commonly,
strong opioids) are important first steps for non-specialists
The evidence for early referral for radiotherapy is strong, although bisphosphonates will have an important role for some patients
Specialist support will be required if pain persists despite initial treatment with behaviour modification, commencement of a non-steroidal
anti-inflammatory drug, and initial titration of a strong opioid
Sources and selection criteria
We searched Medline, Clinical Evidence, and the Cochrane Library using the terms 禁bone metastases禽, 禁pain禽, and 禁bone pain禽 and then
combined these with the specific treatment terms individually. Where possible we have used systematic reviews but not referenced trials
included in these reviews. We limited our search from 1990 to December 2014. We also searched the National Institute for Health and Care
Excellence and the Scottish Intercollegiate Guidelines Network. In calculating the numbers needed to treat, we have assumed a conservative
placebo response of 25%.
over the site of metastasis or pain specifically related to
movement.
A bony metastasis can weaken bone sufficiently such that an
innocuous movement, bump, or fall may result in a pathological
fracture. Vertebral pain should always alert clinicians to the risk
of spinal cord compression, especially in the presence of sensory
disturbance, generalised leg weakness, or changes in bladder
or bowel function. Even without 蒔red flag辞 signs, a full
neurological examination should be done in these patients, with
a low threshold for a spinal magnetic resonance scan.7 Even if
suspicion is low, advice should be sought from the patient而s
oncologist; retrospective cohort studies have shown that being
able to walk at the time of diagnosis of spinal cord compression
is correlated with overall survival and the ability to walk after
treatment. Early diagnosis and treatment of impending spinal
cord compression can drastically improve quality of life for
patients.8 9
Table 1松 outlines the advantages and disadvantages of the
various investigations for suspected cancer induced bone pain.
Generalists may consider plain film radiography or computed
tomography as initial investigations; other investigations are
usually undertaken by specialists.
How is cancer induced bone pain initially
managed?
The first steps in management are simple measures that can be
initiated in non-specialist care, while referral for specialist
treatments such as radiotherapy or bisphosphonates is awaited.
In the following section we describe the evidence for each
treatment that is commonly used for cancer induced bone pain.
Consider specialist referral in any patient where pain persists
despite these initial steps, those with rapidly increasing pain
despite treatment or evidence of toxicity from opioids, and
where pathological fracture or spinal cord compression are
suspected.
Non-drug interventions
Important aspects of managing cancer induced bone pain are to
support patient self management and encourage the use of
non-drug measures. An observational study of 1000 European
patients with cancer showed that in those who had pain on
movement, many of whom had bone metastasis, 43% found
consistent pain relief with non-drug measures, often reported
as either rest or sleep.6 Discussing behaviour modifications,
such as avoiding strenuous movement, and referring patients
for any appropriate movement aids (walking stick, Zimmer
frame) or home adaptations (bath rails) can make important
contributions to the maintenance of function and quality of life.
World Health Organization pain ladder
For cancer pain in general, the mainstay of treatment has been
the World Health Organization而s method for the relief of cancer
pain, commonly known as the analgesic ladder.10 Observational
studies have shown that about 73% of patients achieved adequate
analgesia by following these guidelines, leaving an important
minority of patients with inadequately controlled pain despite
receiving strong opioids.11 12
The first step of the WHO ladder is non-opioid analgesics, such
as paracetamol and non-steroidal anti-inflammatory drugs.
Although some patients find over the counter analgesics helpful,
several systematic reviews that have examined the effectiveness
of paracetamol for cancer pain showed that although it was well
tolerated there was no significant benefit particularly when
added to strong opioids.13 14 Non-steroidal anti-inflammatory
drugs are often perceived to be more efficacious in cancer
induced bone pain than in other pain states, and this is a
reasonable assumption given the major inflammatory
component. However, a well conducted systematic review in
2012 showed some benefit from adding non-steroidal
anti-inflammatory drugs to strong opioids for cancer pain,
although this evidence is limited and weak.13 There are well
reported concerns regarding adverse effects of non-steroidal
anti-inflammatory drugs; however, this systematic review failed
to show any additional harm of adding a non-steroidal
anti-inflammatory drug to a strong opioid.13 The studies did not
perform subgroup analysis on cancer induced bone pain.
Therefore the assertion that non-steroidal anti-inflammatory
drugs are specifically beneficial in cancer induced bone pain
cannot be supported.
The next step in the WHO ladder is the use of weak opioids,
although a systematic review has only shown marginal benefits
of tramadol and codeine in cancer pain, with significant nausea
and vomiting associated with tramadol compared with placebo
or when added to fentanyl. The authors in these studies did not
report the specific proportion of patients with bone metastases.w5
Therefore it is common to miss this step and start low dose
strong opioids if non-opioid analgesia is ineffective.
Strong opioids
Strong opioids are the mainstay of treatment for background
pain in patients with cancer induced bone pain. In the United
Kingdom, the National Institute for Health and Care Excellence
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has published extensive guidance on initiating and managing
strong opioids in palliative care.15 This guidance is not specific
to cancer induced bone pain, but the principles are directly
relevant. Several relatively small randomised controlled trials
found no difference between immediate release and sustained
release morphine in terms of efficacy or side effects when
treatment with opioids was initiated. Therefore this decision
should be based on patient and clinician consensus.16 w6-7
Several different preparations and types of strong opioid are
available. A network meta-analysis showed no important
differences in efficacy between morphine and other strong
opioids.17 Based on one well conducted randomised controlled
trial, about 75% of patients will achieve good pain control with
strong opioids, resulting in a number needed to treat of 2.18
Within this study, however, there was no subgroup analysis for
cancer induced bone pain. Table 2松 provides a summary of the
numbers needed to treat for various treatments for cancer
induced bone pain.
In the United Kingdom, morphine is recommended by NICE
as the preferred opioid treatment in patients who can take oral
drugs. When morphine was compared with oxycodone no
difference was found in pain intensity or adverse effects.17 18
Transdermal opioids (fentanyl or buprenophine) are likely to
be less constipating than morphine or oxycodone.17 Specialist
advice should be sought if pain control is inadequate after the
initial titration of opioid analgesia, or treatment fails.17
Management of incident pain is less satisfactory. This is because
pain manifests within five minutes, is often movement related,
and subsides within 15 minutes in about half of patients with
cancer induced bone pain.w4 Timing drug treatment to coincide
with this pain profile is challenging.
A meta-analysis of fast acting fentanyl preparations found them
to be statistically superior over oral morphine in the treatment
of incident pain.19 When compared with oral morphine, however,
the numbers needed to treat at 10 and 15 minutes after the drugs
have been administered are 18 and 12, respectively.20 This means
that of 12 patients treated with fast acting fentanyl, only one
would have gained benefit after 15 minutes of treatment that
would not have done so had they been treated with morphine.20
Given the additional cost of these preparations, current advice
is to use immediate release morphine preparations as the
preferred treatment and to try a fast acting fentanyl preparation
if this treatment fails. Adverse events are difficult to quantify
in these studies as patients are already taking regular background
opioids. Constipation is a common side effect of opioid
treatment and a laxative should be prescribed at the time
treatment is started.17
Other drug interventions
Adjuvant drugs such as antidepressants and anticonvulsants
may enhance analgesia from strong opioids and can target
neuropathic pain mechanisms. A systematic review in 2011
examined the efficacy of these drugs for the treatment of cancer
pain when added to opioids. A modest reduction in pain scores
was found in patients with a neuropathic element to their pain,
but more adverse effects were reported. Benefit was seen within
4-8 days and did not improve beyond this. These conclusions
are limited owing to the quality of the studies included in the
review.21 Although animal studies have suggested that
gabapentin can have an important analgesic effect in cancer
induced bone pain, there is no evidence confirming the efficacy
of this class of drugs in humans.w8
Currently there is no evidence to support the use of steroids for
cancer induced bone pain; two randomised controlled studies
have shown no sustained benefit for cancer pain.22 23
Lidocaine (lignocaine) patches are not absorbed systemically
and evidence to support their use for cancer induced bone pain
is lacking.w9 w10
What further treatment options are
available?
Once initial treatment has been started, further treatment options
are available to maintain function and quality of life.
Radiotherapy
Radiotherapy has been shown to reduce pain significantly and
is the most effective treatment that is specific for cancer induced
bone pain. Therefore patients with confirmed cancer induced
bone pain should be referred to a clinical oncologist as soon as
possible. A well conducted systematic review comparing single
dose radiotherapy with multiple doses found no important
differences between treatments. Both approaches resulted in a
meaningful improvement in pain for about 60% of patients
(number needed to treat 2.8).24 25 Within this group it was
reported that approximately 25% would be pain-free. This means
that a single dose of radiotherapy can be effective and without
major burden for even very frail patients.
In a well conducted randomised trial of 850 patients, where
most had had an initial response to radiotherapy but recurrence
of pain, 28% experienced a further overall pain response at two
months after re-irradiation. This was also associated with
improved quality of life.26 27
Radioisotopes
Referral to oncology also provides the opportunity to review
hormonal treatment and chemotherapy, as well as to consider
radioisotope treatment. Some evidence, largely from studies in
prostate cancer, indicates that radioisotopes may provide
complete reduction in pain over one to six months, with no
increase in analgesic use, but severe adverse effects
(leucocytopenia and thrombocytopenia) are common.w11
Bisphosphonates
Bisphosphonates such as pamidronate and zoledronate are used
to reduce both pain and skeletal events in patients with bone
metastases. They act by inhibiting osteoclast function. Globally
they are used to prevent skeletal related events and reduce pain
in breast, prostate, and lung cancer as well as multiple myeloma.
In the United Kingdom NICE only recommends early treatment
with bisphosphonates for bone pain associated with breast
cancer.28 NICE advise it can be used in lung and prostate cancer
once palliative measures and radiotherapy have been given.
Several well conducted randomised controlled trials have shown
a persistent reduction in pain scores over years with
bisphosphonates in patients with breast cancer, and although
pain scores increase over time in studies in prostate cancer there
is still a significant difference in favour of bisphosphonate
compared with placebo.29 In a large well conducted randomised
controlled trial in which patients with bone pain from prostate
cancer were randomised to a single infusion of 6 mg of the
bisphosphonate ibandronate or a single 8Gy fraction of
radiotherapy, overall response rates at four weeks were 49%
and 53%, respectively. This non-significant difference was also
similar at 12 weeks.30 This suggests that radiotherapy and
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What to discuss with patients who are starting strong opioids
Address concerns about addiction, tolerance, and side effects, being clear that prescription of strong opioids does not mean patients
are in the last stage of life
Give verbal and written advice on when and how to take opioids for both background and breakthrough pain
Explain how long the pain relief should last and that patients欣 ability to drive may be impaired during initiation of treatment or when doses
are increased
Give advice on signs of toxicity, such as drowsiness, twitching, and hallucinations, and who to contact if any occur out of hours
Provide drugs at the start of treatment, to deal with side effects such as constipation
Offer regular review
Adapted from NICE clinical guideline 140 (http://guidance.nice.org.uk/CG140)
bisphosphonates are equally appropriate and effective
interventions.
A Cochrane review from 2002 examined the effects of
bisphosphonates on cancer induced bone pain and calculated
numbers needed to treat of 11 at four weeks after infusion and
7 at 12 weeks after infusion.31 This review concluded that
although evidence supports the use of bisphosphonates they
should not be considered as first line management, which is in
keeping with the advice from NICE.31 In patients with cancer
induced bone pain from myeloma, a Cochrane review showed
benefit from bisphosphonates in pain management.32
Denosumab
Denosumab is a novel agent that specifically inhibits
RANK-ligand. Clinical trials have shown important benefits in
reducing skeletal related events. One randomised controlled
trial recruited patients with breast cancer with mild levels of
pain. The median time for moderate or severe pain to develop
in those receiving denosumab was significantly delayed when
compared with bisphosphonate zolendronic acid, although there
was no difference in the use of strong analgesics at the end of
the study.33
Interventional procedures
If patients have ongoing complex cancer induced bone pain
despite receiving opioids, radiotherapy, or bisphosphonates,
referral to pain services should be considered. There is good
evidence from a randomised controlled trial that implantable
intrathecal devices lead to a reduction in pain and increased
survival in patients taking high dose opiates for refractory
pain.w12
Surgery
In patients with a good performance status, prophylactic surgery
may be considered for relief of cancer induced bone pain. One
randomised controlled trial showed that percutaneous
stabilisation in the long bones of leg can significantly reduce
pain.w13 Once a pathological fracture has occurred, however,
orthopaedic intervention can stabilise the fracture.
Complementary therapies
Complementary therapies may be considered, but as yet they
are supported by weak evidence. A Cochrane systematic review
of acupuncture acknowledged that there were studies showing
benefit in cancer pain, but that evidence was insufficient to
recommend this as a treatment.w14 Evidence was also insufficient
to support TENS (transcutaneous electrical nerve stimulation),
but one small feasibility randomised controlled trial in patients
with cancer induced bone pain suggests that verbal rating scores
of pain on movement are reduced with active TENS compared
with sham TENS.34 w15 Patients may appreciate non-drug
measures that they can manage themselves and so TENS may
be of value.
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Questions for future research
Why do some bone metastases cause pain and others do not?
What are the disease processes that are responsible for some bone metastases causing pain and others not, and are there any
associations with cancer type?
Are there specific phenotypes of cancer bone pain that might predict response to analgesia?
What is the contribution of spinal hyperexcitability in the experience of bone pain, and how best can this be identified and managed?
What non-drug treatments may offer patients benefit in managing movement related pain?
Tips for non-specialists
The focus of management should be maintenance of function
Non-steroidal anti-inflammatory drugs may be helpful for some patients but most will require strong opioids
Early referral for single fraction radiotherapy should be sought, even in relatively frail patients
Referral for treatment with bisphosphonates can be helpful for some patients
Consider early referral to specialist services in patients with refractory pain despite initial measures
A patientナs perspective
I was diagnosed with cancer on my wedding anniversary a year ago. I developed back pain, which felt exactly the same as sciatica; however,
it wasn欣t getting any better. One Saturday it became so unbearable that I went to A and E and they diagnosed a water infection and sent
me home with antibiotics. I saw my general practitioner and he sent me back to A and E where they did a scan and told me my kidney looked
slightly inflamed. They said it would settle down in a few days with antibiotics. They called me back a few days later to tell me they欣d found
cancer in the bones in my back and my pelvis on the scan I欣d had.
Since then the pain has been bad but it欣s the things that it stops me from doing that I get upset about. I can欣t swim or walk anymore and it
really wears you down. It欣s affected my marriage so we now sleep in separate beds.
I欣ve really appreciated the doctors欣 help but they don欣t understand that I don欣t just want to lie in bed all day, because the tablets have made
me sleepy. I want to be able to do things and this is so important to me. I欣d really like doctors to think about trying to make sure I欣m able to
do things still rather than just giving me tablets.
Additional educational resources
Resources for healthcare professionals
National Comprehensive Cancer Network (www.nccn.org)錦Provides guidelines for the management of adult cancer pain and treatment
of specific cancers (free with registration)
European Society for Medical oncology (www.esmo.org)錦Guidelines for pain management in cancer with access to a smartphone app
National Institute for Health and Care Excellence (www.nice.org.uk)錦Evidence based guidance for specific treatments and an online
treatment algorithm for initiating strong opioids and managing side effects
Resources for patients
Macmillan Cancer Support (www.macmillan.org.uk)錦Provides information and help on cancer and the management of symptoms,
including bone pain; provides links to local support groups in the United Kingdom
Cancer Research UK (www.cancerresearchuk.org)錦Contains information about cancer and the management of specific symptoms
such as pain and includes a forum for patients to discuss their illness
American Cancer Society (www.cancer.org)錦Has general information about bone metastases, and enables patients to search for local
support services in the United States
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Tables
Table 1| Advantages and disadvantages of investigations for bone metastases
DisadvantagesAdvantagesInvestigation
Low sensitivity: requires >50% cortical destruction
to be visible
Universal availability; portable films possible, low costPlain film radiography
Access variable outside large hospitals; high costMore sensitive than plain radiography; best for ribs and pelvic and
shoulder girdles; gives information about soft tissue; can be
reconstructed in three planes
Computed tomography
Relatively low sensitivity; reflects osteoblastic
activity: non-specific
Available widely; whole skeleton assessed; intermediate costTechnetium 99m bone scan
Access limited; high costOptimal images of bone; high sensitivity; detects small metastases
before bone damage occurs; optimal for cord compression; gives
soft tissue and nerve images; whole body magnetic resonance
imaging screens entire skeleton
Magnetic resonance imaging
Access limited; high cost; limited specificity: false
positives can occur
Similar sensitivity to technetium 99m for bone metastases; additional
information about other organs
Fluorodeoxyglucose positron emission
tomography
Limited experience, evidence, and access; high
cost
Most sensitive detection of bone metastasesFluorine positron emission tomography
Access limited but increasing; high costSensitive for prostate cancer metastasesCholine positron emission tomography
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Table 2| Numbers needed to treat values for a meaningful clinical response* for various treatments in cancer induced bone pain
Numbers needed to treatIntervention
2Strong opioids for background pain
12Fast acting fentanyl for incident pain (at 15 mins)
2.8Radiotherapy (meaningful response)
7Bisphosphonates (at 12 weeks)
*Defined as either 30% or 50% reduction in pain scores or an outcome of partial or complete response.
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Figure
Radiological investigations showing bone metastases. A) Bone scan showing metastatic deposits throughout the skeleton.
B) Plain radiography of spine showing lytic vertebral metastasis. C) Plain radiography of a skull showing multiple metastatic
deposits. D) Plain radiography showing a lytic lesion of the upper shaft of the left femur
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2015;350:h315 doi: 10.1136/bmj.h315 (Published 29 January 2015) Page 8 of 8
CLINICAL REVIEW
